A Medical Device Daily

Eclipsys (Atlanta) reported that as an employment inducement following the close of its recent acquisition of Premise (Farmington, Connecticut), it will issue to certain Premise personnel a total of 64,832 shares of Eclipsys common stock, and non-qualified options to purchase a total of 270,138 shares of common stock.

Eclipsys reported earlier this month that it had agreed to acquire Premise for $38.5 million in cash, subject to certain holdback escrow provisions and working capital adjustments (Medical Device Daily, Jan. 5, 2009).

The company said that all of the common stock is subject to contractual restrictions on transfer until vested, 25% of the total number of shares shall vest Dec. 1, 2009, Dec. 1, 2010, Dec. 1, 2011, and Dec. 1, 2012, in each case contingent upon continued employment, with partial pro-rata vesting for time served if employment is terminated by the employee with good reason, or by Eclipsys without cause.

The stock options have a seven-year term, an exercise price per share equal to the fair market value of Eclipsys common stock on the date of grant, and vest over four years, contingent upon continued employment, with partial pro-rata vesting for time served if employment is terminated by the employee with good reason or by Eclipsys without cause.

Eclipsys provides advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services aimed at helping healthcare organizations improve clinical, financial and operational outcomes.

• Navigant Consulting (Chicago), an international consulting firm, said it has acquired The Bard Group (Needham, Massachusetts), a healthcare consulting firm. Financial terms were not disclosed.

• Oleen Pinnacle Healthcare Consulting (Silver Spring, Maryland) said it has acquired Partners in Health Systems (Syracuse, New York), an IT consulting firm. The acquisition creates a more diversified organization capable of offering healthcare IT services to commercial and government sectors, Oleen said.